f CYP2C8. Use caution when administering velpatasvir with cobicistat. Taking these drugs together may increase the plasma concentrations of velpatasvir, potentially resulting in adverse events. Velpatasvir is a substrate of the drug transporters P-glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP); cobicistat is an inhibitor of P-gp and BCRP. Cobicistat is also an inhibitor of the hepatic enzyme CYP3A4. Velpatasvir is a CYP3A4 substrate.
Atorvastatin: Montior patient closely when atorvastatin is coadministered with velpatasvir as this may significantly increase the serum concentrations of atorvastatin, which may increase the risk of myopathy and rhabdomyolysis. Atorvastatin is a substrate of the P-glycoprotein (P-gP) and OATP1B1 transporters as well as CYP3A4, while velpatasvir inhibits P-gp, OATP1B1, and CYP3A4.
Atorvastatin; Ezetimibe: Montior patient closely when atorvastatin is coadministered with velpatasvir as this may significantly increase the serum concentrations of atorvastatin, which may increase the risk of myopathy and rhabdomyolysis. Atorvastatin is a substrate of the P-glycoprotein (P-gP) and OATP1B1 transporters as well as CYP3A4, while velpatasvir inhibits P-gp, OATP1B1, and CYP3A4.
Atropine; Hyoscyamine; Phenobarbital; Scopolamine: Avoid coadministration of sofosbuvir with inducers of P-glycoprotein (P-gp), such as phenobarbital. Taking these drugs together may decrease sofosbuvir plasma concentrations, potentially resulting in loss of antiviral efficacy. Avoid coadministration of velpatasvir with inducers of P-glycoprotein (P-gp) and CYP3A4, such as phenobarbital. Taking these drugs together may significantly decrease velpatasvir plasma concentrations, potentially resulting in loss of antiviral efficacy. Velpatasvir is a P-gp and CYP3A4 substrate.
Azithromycin: Use caution when administering velpatasvir with azithromycin. Taking these medications together may increase the plasma concentrations of both drugs, potentially resulting in adverse events. Both drugs are substrates and inhibitors of the drug transporter P-glycoprotein (P-gp).
Basiliximab: Use caution when administering velpatasvir with basiliximab. Taking these drugs together may increase velpatasvir plasma concentrations, potentially resulting in adverse events. Velpatasvir is a substrate of CYP3A4. Basiliximab may cause a down-regulation of 3A4 activity by increasing IL-2 binding to IL-2 receptors on hepatic and intestinal cells.
Belladonna Alkaloids; Ergotamine; Phenobarbital: Avoid coadministration of sofosbuvir with inducers of P-glycoprotein (P-gp), such as phenobarbital. Taking these drugs together may decrease sofosbuvir plasma concentrations, potentially resulting in loss of antiviral efficacy. Avoid coadministration of velpatasvir with inducers of P-glycoprotein (P-gp) and CYP3A4, such as phenobarbital. Taking these drugs together may significantly decrease velpatasvir plasma concentrations, potentially resulting in loss of antiviral efficacy. Velpatasvir is a P-gp and CYP3A4 substrate.
Bexarotene: Avoid coadministration of velpatasvir with bexarotene. Taking these drugs together may significantly alter velpatasvir plasma concentrations, potentially resulting in loss of antiviral efficacy or adverse effects. Velpatasvir is a substrate of CYP3A4 and CYP2C8; bexarotene is an inducer of CYP3A4 and an in vitro inhibitor of CYP2C8.
Boceprevir: Use caution when administer |
